Success Stories: In Less Than 3 Months, NIW Status Confirmed for a Researcher in Biomedical Science from China, Credit to Our Team of Experts
Client’s Testimonial:
“Thank you very much for your support!”
On April 1st, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: Researcher
Country of Origin: China
Country of Residence at the Time of Filing: China
Approval Notice Date: April 1st, 2022
Processing Time: 2 months, 28 days
Case Summary:
A researcher with a Ph.D. in medical science came to us seeking help with her NIW petition. Hailing from China, her proposed endeavor was to work on the development of disease transmission models, identification of disease-related gene loci, and performance of in-depth studies of widespread diseases such as heart disease and cancer. She wanted to provide tools and frameworks for the development of more effective disease control and prevention policies, as well as medical and clinical strategies, to improve public health and patient outcomes.
This made it clear to us that her research advancing her proposed endeavor is of great importance because it advances scientific knowledge concerning the treatment of and prevention of cardiovascular diseases (CVDs), and economic growth in the global biopharmaceutical market. This is why one of her recommenders said:
“From mechanism to new cancer and cardiovascular treatments, these industries are responsible for saving millions of lives every year, and [the client] has contributed to them through her own discoveries and developments in biomedical science. Her skills in proteomics, and biochemistry find themselves perfectly situated in these industries which are beneficial to global health, as well as the economy.”
At the same time, we noted that her research has resulted in 10 peer-reviewed journal articles (1 of them first-authored) which have been cited a total of 195 times according to Google Scholar. Furthermore, her study has received funding from the National Natural Science Foundation of China (NSFC).
She had obtained 4 letters of recommendation from other experts of which another one said the following:
“Through her numerous contributions to biomedical science, [the client] is well situated to benefit the United States’ historically robust biopharmaceutical and biomedical industries. As [the client’s] research is focused on the diseases on the genetic level, her research is critical for the development of targeted drugs for diseases, such as male infertility, as discussed above. Such expertise makes [the client] a vital asset to the United States, and I strongly urge that her work continues without interruption.”
At the same time, we showed that she has pursued research directly related to her proposed endeavor for 11 years now which granted her the opportunity to do her best in the field. This helped us obtain her NIW approval in a short period of time. We are grateful to her for choosing our firm and our team wishes her the very best.